Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Lupin unveils generic equivalent of Hectorol Injection

      Lupin unveils generic equivalent of Hectorol Injection

      Medical Dialogues Bureau22 Dec 2019 9:40 AM IST
      Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4...
      AstraZeneca-Daiichi breast cancer drug Enhertu gets speedy USFDA nod

      AstraZeneca-Daiichi breast cancer drug Enhertu gets speedy USFDA nod

      Medical Dialogues Bureau22 Dec 2019 9:17 AM IST
      AstraZeneca- Daiichi's drug Enhertu, also known as DS-8201, targets HER2 protein, a major trigger of uncontrolled cell growth in about 20% cases of...
      Novartis wins Medicaid nod for new sickle cell drug Adakveo in 2 US states

      Novartis wins Medicaid nod for new sickle cell drug Adakveo in 2 US states

      Medical Dialogues Bureau22 Dec 2019 9:00 AM IST
      In November, the U.S. Food and Drug Administration approved Adakveo and Global Blood Therapeutic Inc's Oxbryta, which carries a list price of $125,000...
      Glenmark to launch Ryaltris in Australia via partner Seqirus

      Glenmark to launch Ryaltris in Australia via partner Seqirus

      Medical Dialogues Bureau21 Dec 2019 12:07 PM IST
      This paves the way for the launch of Ryaltris in Australia through our partner, Seqirus. Australia will be the first market globally where Ryaltris...
      Novartis Zolgensma lottery-style giveaway upsets patient groups

      Novartis Zolgensma lottery-style giveaway upsets patient groups

      Medical Dialogues Bureau21 Dec 2019 9:15 AM IST
      The company's AveXis unit, which developed the drug- Zolgensma, will give out 50 doses of the treatment through June for babies under 2 years old,...
      Indian Pharmacopoeia recognized by Afghanistan

      Indian Pharmacopoeia recognized by Afghanistan

      Medical Dialogues Bureau21 Dec 2019 9:00 AM IST
      With this, a new beginning has been made and Afghanistan has become the first country to recognize Indian Pharmacopoeia (IP) pursuant to the efforts...
      Panacea Biotec wins Rs 170 crore Pentavalent vaccine orders from UN agencies

      Panacea Biotec wins Rs 170 crore Pentavalent vaccine orders from UN agencies

      Medical Dialogues Bureau20 Dec 2019 1:00 PM IST
      "Panacea Biotec... has received awards worth USD 24.32 million from U N agencies (Unicef and PAHO) for supply of its Easyfive-TT, a fully liquid WHO...
      Lupin partner Concord gets USFDA nod for generic version of Myfortic tablets

      Lupin partner Concord gets USFDA nod for generic version of Myfortic tablets

      Medical Dialogues Bureau20 Dec 2019 12:59 PM IST
      Mycophenolic acid delayed-release tablet is a generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets in the same...
      Sun Pharma arm-SPARC, Bioprojet ink licensing pact for auto-immune diseases drug SCD-044

      Sun Pharma arm-SPARC, Bioprojet ink licensing pact for auto-immune diseases drug SCD-044

      Medical Dialogues Bureau20 Dec 2019 9:45 AM IST
      SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine-1-Phosphate Receptors to treat...
      Merck Ebola vaccine Ervebo gets USFDA okay

      Merck Ebola vaccine Ervebo gets USFDA okay

      Medical Dialogues Bureau20 Dec 2019 9:30 AM IST
      In November, Merck received approval from the European Commission to market Ervebo, less than a month after a European medicines panel backed the...
      FTC seeks to block Illumina from buying PacBio

      FTC seeks to block Illumina from buying PacBio

      Medical Dialogues Bureau20 Dec 2019 9:00 AM IST
      The Federal Trade Commission said in a statement that it filed the antitrust complaint because of concern that Illumina wanted the deal in order to...
      Withdraw decision of NPPA increasing ceiling price of essential life-saving drug; CPI writes to PM

      Withdraw decision of NPPA increasing ceiling price of essential life-saving drug; CPI writes to PM

      Medical Dialogues Bureau19 Dec 2019 1:13 PM IST
      In the letter addressed to Prime Minister Modi, Viswam said, "On behalf of the common people in India, I request you to take immediate steps to...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok